Diaceutics PLC (LON:DXRX – Get Free Report) shares crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of GBX 187.36 and traded as low as GBX 178.50. Diaceutics shares last traded at GBX 184, with a volume of 151,555 shares trading hands.
Analyst Ratings Changes
Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a report on Tuesday. Two research analysts have rated the stock with a Buy rating. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of GBX 215.
View Our Latest Report on Diaceutics
Diaceutics Stock Performance
The company has a current ratio of 2.55, a quick ratio of 9.92 and a debt-to-equity ratio of 5.40. The firm’s fifty day moving average is GBX 187.36 and its 200 day moving average is GBX 160.73. The company has a market cap of £160.17 million, a PE ratio of -589.06 and a beta of 0.88.
Diaceutics (LON:DXRX – Get Free Report) last posted its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. As a group, research analysts predict that Diaceutics PLC will post 1.01 EPS for the current fiscal year.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.
Read More
- Five stocks we like better than Diaceutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
